Using letrozole to improve treatment for glioblastoma
Translational Studies to facilitate Rational Therapeutic Combinations of Letrozole for the Treatment of Glioblastoma
This study is looking at how letrozole, a drug usually used for breast cancer, might help people with recurrent glioblastoma by slowing down tumor growth and making other chemotherapy treatments work better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Cincinnati NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-10662543 on NIH RePORTER |
What this research studies
This research investigates the use of letrozole, a medication typically used for breast cancer, as a potential treatment for glioblastoma, a highly aggressive brain tumor. The study explores how letrozole can reduce tumor growth and enhance the effectiveness of existing chemotherapy drugs like temozolomide. Researchers are conducting pharmacokinetic and pharmacodynamic studies to understand how letrozole crosses the blood-brain barrier and affects tumor cells. The findings from patient-derived cells and ongoing clinical trials suggest promising results for patients with recurrent glioblastoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with recurrent glioblastoma who have not responded to standard treatments.
Not a fit: Patients with low-grade gliomas or those who have not been diagnosed with glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option for patients suffering from glioblastoma, potentially improving survival rates and quality of life.
How similar studies have performed: Previous studies have shown that letrozole can be effective in reducing tumor growth in other cancers, suggesting a potential for success in glioblastoma treatment as well.
Where this research is happening
Cincinnati, United States
- University of Cincinnati — Cincinnati, United States (Active)
Researchers
- Principal investigator: Desai, Pankaj B — University of Cincinnati
- Study coordinator: Desai, Pankaj B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.